Menu
Recruiting NCT06845644

Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients

No phase Interventional Charcot-Marie-Tooth Neuropathy Type 1A Hereditary Transthyretin Amyloid Neuropathy Acquired Demyelinating Neuropathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Quantitative neuromuscular MRI, Neuromuscular ultrasound.
Who it may be relevant to
Registry conditions: Charcot-Marie-Tooth Neuropathy Type 1A, Hereditary Transthyretin Amyloid Neuropathy, Acquired Demyelinating Neuropathy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Longitudinal Quantitative Neuromuscular MRI Evaluation in Patients With Acquired and Hereditary Neuropathy

Overview

The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F). MRI is an imaging technique that enables us to distinguish between muscle and fat tissue, and thus to objectify in vivo structural changes within nerves and muscles in neuropathic patients. In addition to visualizing these changes, quantitative neuromuscular MRI (qMRI) can be used to quantify a number of biomarkers associated with these pathophysiological processes. Over the past few years, this procedure has become a relevant tool in a number of neuromuscular pathologies, such as acquired and hereditary neuropathies. Thanks to its non-ionizing nature and its ability to explore tissues in three dimensions, MRI is the technique of choice for evaluating these diseases, complementing the clinical and electrophysiological scores available. In a context where numerous therapic strategies are being evaluated for the treatment of peripheral nervous system diseases, the clinical and electrophysiological scores currently available are proving inadequate for the detection of early change or a positive therapeutic effect. On the basis of a limited number of studies, quantitative MRI could provide much more sensitive therapeutic monitoring data over short periods of time which is crucial for future therapeutic trials. The most interesting MRI biomarker to date would therefore be the FF, which represents the percentage of fatty infiltration of muscles following pathological nerve damage. Other MRI biomarkers, such as quantified magnetization transfer ratio (MTR), proton density (PD), water transverse relaxation time (wT2) and three-dimensional volume, enable us to study the degenerative and inflammatory phenomena at work in these neuropathies from different angles, detailing the nerve and muscle damage in patients compared with healthy controls or presymptomatic patients. In patients with Charcot-Marie-Tooth (CMT) neuropathy in particular, qMRI is the only tool to detect significant longitudinal variation over a one-year period, revealing an average increase in FF in the lower limbs of +1.5% over 12 months. Confirmation of these results and their extension to other neuropathies such as hereditary amyloid neuropathies (ATTR-PN) or acquired demyelinating neuropathies (ADN) is therefore justified, but requires the implementation of standardized longitudinal studies including these different pathologies. As strong correlations between these MRI biomarkers and the main clinical scores have been demonstrated in several cross-sectional studies, the clinical value of this non-invasive tool is beyond doubt. The main limitation to the clinical deployment of this technology remains the time required for the manual segmentation step to delineate the areas of interest. The ongoing development of new image analysis techniques, as well as the contribution of artificial intelligence and deep learning to the imaging data extraction process, are well on the way to solving this problem, but require continuous updating of practices to identify the most interesting MRI biomarkers, facilitate their extraction and thus measure their clinical application with a view to future therapeutic trials.

Interventions

  • Other Quantitative neuromuscular MRI
    Quantitative neuromuscular MRI is used to quantify a number of biomarkers associated with these pathophysiological processes
  • Other Neuromuscular ultrasound
    Neuromuscular ultrasound is used to quantified nerve diameter variation

Primary outcome measures

  • Annual intramuscular fat fraction progression [Time frame: Between inclusion and one year after]
Secondary outcome measures (7)
  • Annual percentage change in magnetization transfer ratio (MTR) [Time frame: Between inclusion and one year after]
  • Annual percentage change in proton density (PD) [Time frame: Between inclusion and one year after]
  • Annual percentage change in transverse relaxation time (T2) [Time frame: Between inclusion and one year after]
  • Annual percentage change in 3D volume [Time frame: Between inclusion and one year after]
  • Correlations between MRI parameters and patients' clinical and electrophysiological parameters [Time frame: Between inclusion and one year after]
  • Annual variation of nerve diameter in ATTR-PN patients [Time frame: Between inclusion and one year after]
  • Correlation betxeen ultrasound-quantified nerve diameter variation and clinical and electrophysiological parameters in ATTR-PN patients [Time frame: Between inclusion and one year after]

Eligibility criteria

Inclusion criteria

  • Male or female between 18 and 80 years of age,
  • Patients who have freely given their consent to participate in this study,
  • Patient with genetically confirmed hereditary CMT neuropathy
  • or patient with an acquired demyelinating neuropathy such as typical PIDC or anti-MAG of typical form
  • or a patient with a genetically confirmed pathogenic mutation in the transthyretin (TTRn) gene,
  • Patients who are beneficiaries or entitled beneficiaries of a social security scheme.

Exclusion criteria

  • Patients with co-morbidity or a history of other peripheral neuropathy,
  • Patients with alcohol or psychoactive substance abuse,
  • Patients with contraindications to MRI exploration: claustrophobia, pacemakers, Holter systems, IUDs, metal surgical clips, metal prostheses or implants (or other metal foreign bodies),
  • Patient unable to perform the MRI due to severe handicap,
  • Patient in a period of exclusion from another research protocol at the time of signing the consent/non-opposition form,
  • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women),
  • Persons who cannot read and understand the French language well enough to be able to give their consent to participate in research.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • Assistance - Publique Hôpitaux de Marseille — Marseille

Identifiers

NCT: NCT06845644 · RCAPHM24_0268 · ID-RCB

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗